Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Los Angeles, California 90045, United States
Maroorchydore, Queensland 4558, Australia
Ottawa, Quebec K1H 8L6, Canada
Hangzhou, Zhejiang, 100142, China
Taichung City, 40447, China
Keil, 24105, Germany
Athens, Attiki, 15562, Greece
Beer Jacob, 73100, Israel
Sittard-Geleen, 6162 BG, Netherlands
Cape Town, 7500, Senegal
Gauteng, 1820, South Africa
Val de Grace, 0184, South Africa
Majadahonda, Madrid, 28222, Spain
Niao-Sung Hsiang Kaohsiung County, 83301, Taiwan
Tapei, Beitou Dist., 11217, Taiwan
Tapei, 10002, Taiwan
Kadiköy/Istanbul, 41380, Turkey (Türkiye)
Zaporizhia, 69063, Ukraine